{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:06:27Z","timestamp":1773957987027,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.iliver.2026.100220","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:38:12Z","timestamp":1768718292000},"page":"100220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Somatostatin analog therapy in delaying progression of polycystic liver disease: A meta-analysis with trial sequential analysis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0113-5117","authenticated-orcid":false,"given":"Mohammed S.","family":"Beshr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana H.","family":"Shembesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-619X","authenticated-orcid":false,"given":"Bisher","family":"Sawaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-2192","authenticated-orcid":false,"given":"Shahem","family":"Abbarh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abu-Rumaileh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tincopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-4212","authenticated-orcid":false,"given":"Muhammed","family":"Elhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iliver.2026.100220_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7180\/kmj.23.128","article-title":"Polycystic liver disease: an overview of clinical manifestations, diagnosis, and treatment","volume":"38","author":"Jeong","year":"2023","journal-title":"Kosin Med J"},{"key":"10.1016\/j.iliver.2026.100220_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-pathol-042320-121247","article-title":"Polycystic liver disease: advances in understanding and treatment","volume":"17","author":"Masyuk","year":"2022","journal-title":"Annu Rev Pathol"},{"issue":"10174","key":"10.1016\/j.iliver.2026.100220_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.iliver.2026.100220_bib5","series-title":"Treasure Island (FL): Statpearls Publishing Copyright \u00a9 2025","article-title":"Polycystic liver disease. StatPearls","author":"Kothadia","year":"2025"},{"key":"10.1016\/j.iliver.2026.100220_bib6","doi-asserted-by":"crossref","DOI":"10.7326\/aimcc.2024.0509","article-title":"A glimpse into isolated polycystic liver disease: image case","volume":"4","author":"Del Rio","year":"2025","journal-title":"AIM Clinical Cases"},{"key":"10.1016\/j.iliver.2026.100220_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i679","article-title":"Autosomal dominant polycystic kidney disease","author":"Simms","year":"2016","journal-title":"Bmj"},{"issue":"19","key":"10.1016\/j.iliver.2026.100220_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2025.0310","article-title":"Autosomal dominant polycystic kidney disease: a review","volume":"333","author":"Chebib","year":"2025","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.iliver.2026.100220_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/cells14151203","article-title":"Mechanistic insights into the pathogenesis of polycystic kidney disease","volume":"14","author":"Al-Orjani","year":"2025","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.iliver.2026.100220_bib10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.iliver.2026.100220_bib13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2215\/CJN.13661119","article-title":"Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial","volume":"15","author":"Hogan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100220_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease","volume":"157","author":"van Aerts","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.iliver.2026.100220_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.iliver.2026.100220_bib16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.iliver.2026.100220_bib17","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2024"},{"issue":"2","key":"10.1016\/j.iliver.2026.100220_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.17085\/apm.21038","article-title":"Trial sequential analysis: novel approach for meta-analysis","volume":"16","author":"Kang","year":"2021","journal-title":"Anesth Pain Med"},{"issue":"9","key":"10.1016\/j.iliver.2026.100220_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.iliver.2026.100220_bib20","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.iliver.2026.100220_bib22","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.iliver.2026.100220_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100220_bib24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"9903","key":"10.1016\/j.iliver.2026.100220_bib25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.iliver.2026.100220_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100220_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02812-z","article-title":"The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Garofalo","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.iliver.2026.100220_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12882-017-0578-6","article-title":"The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression","volume":"18","author":"Neijenhuis","year":"2017","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2050640617705577","article-title":"Impact of liver volume on polycystic liver disease-related symptoms and quality of life","volume":"6","author":"Neijenhuis","year":"2018","journal-title":"United Eur Gastroenterol J"},{"issue":"25","key":"10.1016\/j.iliver.2026.100220_bib33","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.iliver.2026.100220_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2215\/CJN.0000000000000049","article-title":"Effects of octreotide-long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial","volume":"18","author":"Trillini","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100220_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40268-021-00342-7","article-title":"Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation","volume":"21","author":"Aapkes","year":"2021","journal-title":"Drugs R&D"},{"issue":"8","key":"10.1016\/j.iliver.2026.100220_bib36","first-page":"408","article-title":"Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors","volume":"10","author":"Ayyagari","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12876-022-02142-y","article-title":"Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study","volume":"22","author":"Aapkes","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.iliver.2026.100220_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/liv.13965","article-title":"Severity in polycystic liver disease is associated with aetiology and female gender: results of the International PLD Registry","volume":"39","author":"van Aerts","year":"2019","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.iliver.2026.100220_bib39","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.14986","article-title":"Estrogens in polycystic liver disease: a target for future therapies?","volume":"41","author":"Aapkes","year":"2021","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.iliver.2026.100220_bib40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jgh.16785","article-title":"Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization","volume":"40","author":"Zhu","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.iliver.2026.100220_bib41","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:03:19Z","timestamp":1773943399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947826000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772947826000046"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100220","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatostatin analog therapy in delaying progression of polycystic liver disease: A meta-analysis with trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100220"}}